Centessa Pharmaceuticals (NASDAQ:CNTA) Sets New 52-Week High – What’s Next?

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA)’s share price reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $40.26 and last traded at $40.2850, with a volume of 5890990 shares traded. The stock had previously closed at $40.18.

Analysts Set New Price Targets

Several research firms recently weighed in on CNTA. Truist Financial lowered shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 target price on the stock. in a report on Monday, April 13th. Wells Fargo & Company downgraded Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and increased their price target for the company from $35.00 to $42.00 in a report on Monday, April 20th. Guggenheim lowered Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 2nd. Leerink Partners cut Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and boosted their price objective for the stock from $36.00 to $40.00 in a research note on Wednesday, April 1st. Finally, Wolfe Research downgraded Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research report on Tuesday, March 31st. Four equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $41.33.

Centessa Pharmaceuticals Stock Up 0.5%

The company has a debt-to-equity ratio of 0.23, a current ratio of 9.53 and a quick ratio of 9.53. The stock has a market capitalization of $6.30 billion, a price-to-earnings ratio of -22.74 and a beta of 1.11. The firm’s fifty day moving average is $39.72 and its 200-day moving average is $31.51.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.14). On average, sell-side analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of CNTA. Foresite Capital Management VI LLC raised its position in shares of Centessa Pharmaceuticals by 4.8% during the 3rd quarter. Foresite Capital Management VI LLC now owns 1,314,019 shares of the company’s stock valued at $31,865,000 after acquiring an additional 60,640 shares in the last quarter. SG Americas Securities LLC lifted its stake in Centessa Pharmaceuticals by 1,017.7% during the fourth quarter. SG Americas Securities LLC now owns 263,625 shares of the company’s stock worth $6,593,000 after purchasing an additional 240,039 shares during the last quarter. Royce & Associates LP acquired a new position in Centessa Pharmaceuticals in the third quarter worth $5,999,000. Cinctive Capital Management LP acquired a new position in Centessa Pharmaceuticals in the third quarter worth $2,246,000. Finally, Avoro Capital Advisors LLC boosted its holdings in Centessa Pharmaceuticals by 116.2% in the third quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock worth $262,096,000 after purchasing an additional 5,808,080 shares during the period. Institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.